Loading...

Martin Kabongo

Title(s)Recall Hcomp, Family Medicine and Public Health
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #0807
La Jolla CA 92093
Phone8/6-57--7750
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Kabongo's global health research interests center around the long term impacts of short trip interventions in targeted populations abroad.

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine. 2013 Nov 04; 31(46):5300-5. Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT. PMID: 23727002.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    2. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-? T cell responses in humans. Vaccine. 2013 Mar 25; 31(13):1752-8. Peters W, Brandl JR, Lindbloom JD, Martinez CJ, Scallan CD, Trager GR, Tingley DW, Kabongo ML, Tucker SN. PMID: 23357198.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    3. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis. 2010 Nov 01; 202(9):1327-37. Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S, Jeanfreau RJ, Ghosh MR, Kabongo ML, Gittleson C, Karron RA. PMID: 20874515.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCellsPHPublic Health
    4. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine. 2010 Mar 16; 28(13):2565-72. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, Al-Ibrahim MS, Kabongo ML, Steigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB. PMID: 20117262.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsCTClinical Trials
    5. Diagnostic error in medicine: analysis of 583 physician-reported errors. Arch Intern Med. 2009 Nov 09; 169(20):1881-7. Schiff GD, Hasan O, Kim S, Abrams R, Cosby K, Lambert BL, Elstein AS, Hasler S, Kabongo ML, Krosnjar N, Odwazny R, Wisniewski MF, McNutt RA. PMID: 19901140.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans